Heart failure with preserved ejection fraction (HFpEF) represents approximately 50% of the overall heart failure (HF) population 1 , yet relatively few prognostic markers are used in routine clinical practice. Clinicians commonly assess symptom severity, prior HF hospitalizations, natriuretic peptide levels and comorbidity burden to characterize disease trajectory. Furthermore, without disease-modifying agents, the management of HFpEF is largely limited to optimization of volume status and comorbid conditions 2 . In contrast, for patients with HF with reduced EF (HFrEF), clinicians incorporate an array of data from clinical evaluation and diagnostic testing to risk-stratify patients, individualize guideline-based medication regimens and determine optimal timing for implantable devices and advanced therapies. For instance, thresholds for echocardiographic and exercise testing parameters (e.g., EF and maximal oxygen consumption)
are central components of the decision-making process for defibrillator implantation and advanced therapies such as ventricular assist devices 2 . An equivalent prognostic marker to EF has not been identified for HFpEF patients despite the similarly high event rate compared to HFrEF cohorts 3, 4 .
Given that HFpEF patients have normal systolic function as quantified by EF, measures of diastolic dysfunction on echocardiography (e.g., myocardial tissue relaxation and ventricular inflow patterns) have been used to characterize disease severity 5 . However, these parameters have modest sensitivity and specificity 6, 7 . An alternative diagnostic measure that captures the underlying myocardial abnormality in HFpEF with superior fidelity would help with both diagnostic and prognostic dilemmas. For instance, such a test could help determine if progressive dyspnea was due to worsening HF or whether another disease process (e.g., lung disease) should be investigated. Moreover, if the parameter was shown to be modifiable with therapy and modulation translated into improved clinical outcomes, this would change the landscape of echocardiographic and exercise testing parameters (e.g., EF and maximal oxygen n n co co cons ns nsum um umpt pt ptio io ion n) n are central components of the decision-making process for defibrillator implantation and adva a anc nc nced ed ed t t the he hera r pi i ies es s such as ventricular assist devi vi vice ce ces 2 . An equivalent pr pr rog og ognostic marker to EF h ha has not been i ide de den nt nti ifie ie ed d d fo fo for r r HF HF HFpE pE pEF F F p p pati ti tien nts d d des spite e t t the si si simi mi mila la larl r r y y hi hi high gh gh e e eve v v n nt r rat at ate e e co co omp mp mpar ar ared ed ed t t to o o HF HF HFrE rE rEF coho o ort rt rts 3, 4 .
Gi Gi Give e ven n n th th that at at H H HFp Fp FpEF EF EF p p pat at atie ie ient nt nts s s ha ha have e ve n n nor or orma ma mal l l sy s syst st stol ol olic ic ic f f fun n unct ct ctio io ion n n as as as Myocardial deformation imaging using two-dimensional (2D) speckle-tracking strain echocardiography (STE) is the 2D tracking of unique speckle patterns created by the constructive and destructive interference of ultrasound beams within tissue. These speckles are tracked on a frame-by-frame basis and the accuracy of speckle-tracking has been validated against sonomicrometry and tagged cardiac magnetic resonance imaging 9 . Strain reflects the global deformation of ventricular myocardium during the cardiac cycle, is typically measured at peak systole (i.e., aortic valve closure) for systolic strain, and can be determined in the longitudinal, radial, and circumferential planes 9 . Longitudinal systolic strain is more reproducible and may be less susceptible to technical factors that limit EF assessments by conventional 2D echocardiography (2DE) 10 .
Measurement of LS by 2D-STE has also emerged as a more sensitive index of myocardial systolic performance than EF 9 . Measurements of EF by 2DE principally assess load dependent changes in LV cavity size that may not reflect actual myocardial systolic function 11 .
In comparison, LS can detect subtle systolic dysfunction despite preserved global EF in HFpEF, 12 cardiac amyloidosis, 13 and patients receiving cardiotoxic chemotherapy 14 .
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disease, and cardiac amyloidosis 15 . However, prior to the current publication, limited data were available regarding the prognostic utility in HFpEF patients 16 These data from a fairly large cohort of well-characterized HFpEF patients provide important insights into the potential role for routine use of strain imaging in prognostication. One takeaway message is that impaired LS, as specifically defined and assessed in the context of the TOPCAT trial dataset and core laboratory, was an independent prognostic marker in HFpEF with greatest value in predicting CV death. The strengths of the study include the robust methodology involving strain evaluation in a core laboratory, blinded endpoint adjudication and rigorous statistical techniques to assess implications of missing data and specifically evaluate the o those with EF 55% or in a subgroup with adjustment for natriuretic peptide leve ve vel. l. l. H H How ow owev ev ever er er, when the incremental value of impaired LS for risk prediction was assessed through additional tatis is sti ti tica ca cal l l te te tech ch chniqu qu ques, LS provided marginal addi di diti ti tiv v ve utility beyond con nv nven e e tional measures for However, several considerations need to be highlighted when interpreting these data.
First, these data are from a clinical trial dataset which has important differences from the broader population of HFpEF patients. For instance, despite TOPCAT's entry criteria requiring age 50 years, the trial population was significantly younger than HFpEF patients in community cohorts 18 . Moreover, the analysis cohort in the present study was a subgroup of a trial subgroup.
The TOPCAT echocardiography substudy included 27% of the overall study population and adequate strain data were available in 14%. The echocardiography substudy population had notable differences from the overall trial cohort and additional differences were seen when comparing those with adequate quality strain data versus those without. Furthermore, while having an expert core laboratory using vendor-independent speckle-tracking software previously demonstrated to have good reproducibility for longitudinal strain 19 is a strength for assessing efficacy under optimal conditions, the effectiveness in the real-world is unknown. Currently, there are inherent limitations to the widespread use of strain echocardiography, including dependency on high quality images, variability related to different vendor acquisition and analysis platforms as well as uncertainty regarding normal cut-off values and inter-institutional reproducibility. These observations do not necessarily discredit the findings, but rather, should highlight some degree of uncertainty with respect to generalizability.
In addition, the models for the analysis of the incremental value of LS over conventional clinical and echocardiographic variables demonstrated an unexpected finding. Previous analyses suggest that clinical variables are usually better able to predict fatal events (i.e., higher c-index) adequate strain data were available in 14%. The echocardiography substudy popul ul ulat at atio io ion n n ha ha had d d notable differences from the overall trial cohort and additional differences were seen when t comp mp mpar ar arin in ing g g th th those e e wi w w th adequate quality strain da ata ta ta v v versus those without. t. t. F F Furthermore, while h ha hav vi ving an expe e ert rt rt c cor r re e e a la labo bo bora ra rato to tory ry ry u u usi si sing ng ng v vendo d d r r r-ind dep p pen n nde de dent nt nt s s spe pe peck ck ckle e e t -t tra ra rack c cking g g s s sof of oftw tw twar ar are pr pr prev ev evio io ious us usly l de e emo mo monstrated ed ed to ha a ave go oo o d re re repr pr produc uc ucib bili it ity y f fo for r r lon ngi i itud d din n nal l st tr trai a a n n n 19 9 9 is s s a st treng ng ngth th th for r r a a asse ess s sing ef ef effi fi fica ca cacy c cy und nd nder er er o o opt pt ptim im imal al al c c con on ondi di diti ti tion on ons s s, t t the he he e e eff ff ffec ec ecti ti tive e ven n nes es ess s s in in in t t the he he r r rea ea eal l l-wo o worl rl rld d d is is is unk nk nkno no nown n wn. Cu C Curr rr rren en entl tl tly, than rehospitalization events in HF populations. For instance, in the OPTIMIZE-HF risk model of acute HF patients, the c-index for the multivariable model of death was 0.74 compared to 0.64 for the composite of death or hospitalization 20 . It is interesting to note that the predictive capacity of the clinical and echocardiographic parameters used in the present analysis was greater for HF hospitalization than for CV death (0.74 vs. 0.66, respectively, for the models without LS). The specific reasons for these findings are uncertain but suggest that future work is needed to assess the added value of LS for the prediction of clinical events.
In the end, the question lies in how these results should be incorporated into our subsequent clinical behavior. These data suggest that there is a strong association between abnormal LS and worse outcomes, particularly CV death, but that the incremental value beyond conventional risk predictors is modest. Nonetheless, we view these data from the perspective of the glass half full. Given the limited resources available to objectively characterize HFpEF disease severity, LS has the potential to help inform clinical practice. These patients will likely have one (or more) echocardiograms performed serially and the added time, expense, and expertise to assess LS may be balanced by the incremental knowledge gained. However, these results should be validated in independent datasets prior to broad application.
In addition, several questions warrant further study. First, can strain interpretation be similarly performed amongst the broad population of clinical providers? Second, is a threshold value of 15.8% optimal for sensitivity and specificity of LS in HFpEF? Finally, the finding that LS can improve with spironolactone therapy is intriguing and requires further study. Despite the clearly articulated limitations of the subgroup analyses, these findings provide mechanistic data to support the observation of reduced HF hospitalizations with spironolactone in HFpEF patients enrolled in the Americas. For HFpEF patients, these new observations add insights into the abnormal LS and worse outcomes, particularly CV death, but that the incremental al al v v val al alue ue ue b b bey ey eyon on ond conventional risk predictors is modest. Nonetheless, we view these data from the perspective of he gl gl glas as ass s s ha ha half lf lf ful l ll l l. G Given the limited resources av av vai ai aila l l ble to objectively c c cha h h racterize HFpEF d di dise e ease severi ity y y, L LS h h has as as t t the he he p p pot ot oten en nti ti ia a al l l to to t hel l lp p p in nform rm m cli i ini ni nica ca al l p p prac ac actice ce ce. T Th The ese pa pa pati ti tien en ents ts ts w w wil il ill li li like ke kely ly ly ha a ave ve ve one (or or r m m mor r re) ) ec ch ho oc o ard d diog og ograms ms ms p p per r rform rm me e ed ser er ri iall l ly y y an nd d d th th the e ad ad adde de ed t t tim me, ex x xpe p n ns nse e e, and nd d ex e expe pe pert rt rtis is ise e e to to to a a ass ss sses es ess s s LS LS LS m m may a ay b b be e e ba ba bala la lanc nc nced ed ed b b by th th the e e in in incr cr crem em emen en enta ta tal l l kn kn know o owle le ledg dg dge e e ga ga gain in ined ed ed. Ho Ho Howe e weve e ver r r, t t the he hese se se biologic basis for improved outcomes and support initiating spironolactone with the usual appropriate monitoring. In addition, these mechanistic observations lay the foundation for future work to validate the potential role of LS as a surrogate marker for investigation of novel drugs to treat HFpEF.
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